National Hispanic TV Network fka GECC

[xrayview]

Press Release Source: Contemporary Solutions, Inc.

Contemporary Solutions Announces ShimodaAtlantic Launch of New Vertigo Drug Verticil
Monday July 25, 12:47 am ET

LAS VEGAS--(BUSINESS WIRE)--July 25, 2005--Contemporary Solutions, Inc.(OTC:CMPN - News) announces that ShimodaAtlantic, Inc., a 20% subsidiary of Contemporary Solutions, Inc., is launching a new non-prescription vertigo drug: Verticil(TM).

ShimodaAtlantic(TM), Inc. of Las Vegas, Nevada, will begin deliveries to selected retail outlets of its new non-prescription oleander extract during the first week of August, 2005. The new item, retailing under the name Verticil(TM), will sell for $12.95, and is packaged in a 30ml (1 oz.) bottle with an integral dropper for dosage measurement.

The formulation of Verticil(TM), a liquid, is the maximum possible strength for a non-prescription oleander extract, according to company officials. The drug is made from organically grown oleander plants. It is intended for its labeled indication of vertigo.

Vertigo is a symptom, rather than a disease according to the National Institutes of Health (NIH), and affects 40% of the American population at least once in their lifetime. The principal active ingredient in Verticil(TM) is oleandrin. There are an additional 60 other naturally occurring substances in the extract.

ShimodaAtlantic(TM) also makes a prescription oleander-based drug, and is currently proceeding to clinical trials in the US to determine if the drug is effective against solid tumor cancers and certain viruses. The prescription version is marketed under the name Xenavex(TM). A series of scientific papers published by M.D. Anderson Cancer Center researchers since 2000 suggest that oleander extract may be an extremely effective anti-tumor agent. A May, 2005 study sponsored by the NIH study found that cardioglycosides like Xenavex(TM) may be effective in treating cystic fibrosis.

Verticil(TM) will also be available beginning in mid-August via an independent distributor's e-commerce and retail operation located in Bentonville, Arkansas.

ShimodaAtlantic is privately held. In June 2005, publicly-held Contemporary Solutions, Inc. (OTC:CMPN - News) purchased a 20% interest in ShimodaAtlantic, Inc. Verticil(TM), C-Trial(TM), and Xenavex(TM) are trademarks of ShimodaAtlantic, Inc.

This press release contains "forward-looking statements" within the meaning of Private Securities Litigation Reform Act of 1995. Such statements can be identified by lead-in "Looking Forward." These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements as a result of the effectiveness of management's strategies and decisions, general economic and business conditions, new or modified statutory or regulatory requirements, and changing price and market conditions.

Contact:

Princeton Research, Inc. (for Contemporary Solutions)
Mike King, 702-650-3000
or
ShimodaAtlantic, Inc.
www.shimoda-atlantic.com
310-401-6712, ext. 224

http://biz.yahoo.com/bw/050725/245019.html?.v=1